BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026

Rhea-AI Summary

BioStem Technologies (OTC: BSEM) will release its second quarter 2026 financial results on Wednesday, August 12, 2026, followed by a conference call and webcast at 4:30 PM ET. The event will feature an overview of the quarter from BioStem management.

According to the company, investors can join via North America toll-free line (800) 715-9871, international line +1 (646) 307-1963, using Conference ID 9695874, or through the webcast at https://events.q4inc.com/attendee/199151484. BioStem focuses on perinatal tissue allograft products and leverages its proprietary BioRetain®, CryoTek® and SteriTek® technologies across brands including Neox®, Clarix®, VENDAJE® and American Amnion™.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 4:30 PM ET

POMPANO BEACH, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET.

The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE.

Conference Call & Webcast Information:

• Conference ID: 9695874
• North America Toll-Free: (800) 715-9871
• International Toll: +1 (646) 307-1963
• Webcast Link: https://events.q4inc.com/attendee/199151484
  
  

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain^®, CryoTek^® and SteriTek^® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox^®, Clarix^®, VENDAJE^® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
ir@biostemtech.com

Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com

FAQ

When will BioStem Technologies (OTC: BSEM) report its Q2 2026 financial results?

BioStem Technologies will report its second quarter 2026 financial results on Wednesday, August 12, 2026. According to the company, the release will be followed by a management-hosted conference call and webcast providing an overview of the quarter’s performance and key developments.

What time is the BioStem Technologies (BSEM) Q2 2026 earnings conference call on August 12, 2026?

The BioStem Technologies Q2 2026 conference call and webcast is scheduled for 4:30 PM ET on August 12, 2026. According to the company, the call will feature an overview of the quarter by BioStem management for investors and analysts.

How can investors join the BioStem Technologies (OTC: BSEM) Q2 2026 earnings call by phone?

Investors can join the BioStem Technologies Q2 2026 call via North America toll-free (800) 715-9871 or international +1 (646) 307-1963. According to the company, participants should reference Conference ID 9695874 to access the live earnings discussion.

Is there a webcast link for the BioStem Technologies (BSEM) Q2 2026 earnings presentation?

Yes. BioStem Technologies will provide a live webcast at https://events.q4inc.com/attendee/199151484 for its Q2 2026 results. According to the company, the webcast will include a management overview of the quarter and can be accessed after online registration.

What does BioStem Technologies do in regenerative medicine for investors researching BSEM?

BioStem Technologies is a regenerative medicine company focused on perinatal tissue allograft products. According to the company, it develops, manufactures and commercializes solutions using proprietary BioRetain®, CryoTek® and SteriTek® technologies under brands like Neox®, Clarix®, VENDAJE® and American Amnion™.

How is BioStem Technologies (BSEM) regulated and accredited for its perinatal tissue allografts?

BioStem Technologies’ quality management system and procedures are accredited by the American Association of Tissue Banks (AATB). According to the company, its systems follow current Good Tissue Practices (cGTP) and Good Manufacturing Practices (cGMP) for its perinatal tissue allograft portfolio.